All In Biotech

Free tool

FAERS Monitor: Tecvayli

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761291 or its brand name (Tecvayli, Teclistamab-Cqyv). Reports on generic versions are filed under their own applications.

Reports

2,379

Serious

1,947

82% of reports

Hospitalization

578

Death reported

444

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cytokine release syndrome582
  • immune effector cell-associated neurotoxicity syndrome211
  • off label use199
  • death155
  • infection136
  • plasma cell myeloma131
  • neutropenia116
  • fatigue99
  • pyrexia94
  • pneumonia92
  • covid-1988
  • drug ineffective73
  • diarrhoea65
  • product dose omission issue57
  • neuropathy peripheral52

Reports by year received

View as table
YearReports
202211
2023408
2024616
2025772
2026572

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,780 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
immune effector cell-associated neurotoxicity syndromeSignal211326.5286.365,746
cytokine release syndromeSignal582264.1245.8148,036
plasma cell myelomaSignal13129.825.23,610
infectionSignal1368.37.1873
neutropeniaSignal1167.56.3656
neuropathy peripheralSignal524.83.7155
covid-19Signal884.43.6233
pneumoniaSignal922.52.184
pyrexiaSignal942.42.077
off label useSignal1992.01.8104
product dose omission issue571.71.316
death1551.61.435
fatigue991.10.91
diarrhoea650.90.71
drug ineffective730.50.441

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.